ROXADUSTAT GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES BY THE U.S. FOOD AND DRUG ADMINISTRATION
FIBROGEN INC - TO FILE PHASE 3 PROTOCOL IN Q4 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.